Stock·NYSE·Healthcare
Stryker Corp. (SYK)
- Market cap
- $112.48B
- P/E
- 29.18
- Dividend yield
- 1.20%
- Street target
- $360.00median of 29 analysts
- 52-week range
- $267.00 $392.55
The short version
Where SYK stands today, in four lines, and what CleaRank Financial AI makes of it.
SYK at a glance
Stryker Corp. (SYK): Buy, 77/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($300.80 and $326.94).
- Earnings SYK beat estimates in 7 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $738.2M and made no open-market purchases over the last 18 months.
- Valuation P/E of 29.2 against 31.9 for the Healthcare sector: broadly in line with peers (-9%).
Figures as of October 16, 2026.
CleaRank Financial AI
The medical device sector, represented by the XLV ETF, has a median P/E of 31.9 and revenue growth of 8.1%. Stryker's P/E of 29.18 is slightly below the sector average, while its revenue growth of 9.4% slightly exceeds it. The company's debt-to-equity ratio of 0.64 is in line with sector averages. Key risks include significant insider selling and the stock's current positioning below key moving averages.
Only on CleaRank
Figures we compute ourselves from SYK's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $293.23 is 2.5% below the 50-day simple moving average of $300.80.Price above its 200-day average ›
The price is 10.3% below the 200-day simple moving average of $326.94.50-day average above the 200-day ›
The 50-day average ($300.80) is 8.0% below the 200-day average ($326.94), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 21% of its 52-week range, between $267.00 and $392.55.
SYK share price
Pick a period: each tab shows how far SYK has moved over it, to the last close.
Today's trading
Where SYK sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 29.18 is 8.5% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 4.18 is 23.0% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $3.7B on revenue of $25.8B, a net margin of 14.4%.Beat estimates in most recent reports ›
SYK beat the EPS estimate in 7 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.20%, or $3.52 a share a year.
Key statistics
The headline figures for SYK.
As of October 16, 2026, SYK trades at $293.23, with a market value of $112.48B, a P/E ratio of 29.18 and a dividend yield of 1.20%.
What the numbers say
CleaRank Financial AI's reading of SYK's valuation, growth and risks.
The company demonstrates strong operational efficiency with a profit margin of 14.43% and an operating margin of 27.02%. Its return on equity is a healthy 16.51%, exceeding the sector median of 7.3%. The debt-to-equity ratio is 0.64, which is in line with the sector average. Revenue growth of 9.4% outpaces the sector average of 8.1%, indicating solid expansion.
SYK against the Healthcare sector
How SYK compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-9% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 5, 2025, SYK has lost 23.1% against a gain of 28.9% for XLV.
Performance against XLV
SYK and the Healthcare sector fund over the same days.
Revenue and earnings
How much SYK sells, and how much of it becomes profit.
Revenue growth: Revenue grew 11.2% in FY2025 to $25.1B, from $22.6B a year earlier.
Profit margin: The net margin was 12.9% in FY2025, down from 13.2% the year before.
Profitable: SYK earned $3.2B in FY2025.
Earnings reality check
Did SYK beat what analysts expected, and how did the stock react?
Earnings record: SYK beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $3.49 | $3.69 | +5.73% | -6.42% | -3.05% |
| Apr 30, 2026after close | $2.98 | $2.60 | -12.75% | -6.47% | -6.63% |
| Jan 29, 2026after close | $4.40 | $4.47 | +1.59% | +4.31% | +2.29% |
| Oct 30, 2025after close | $3.13 | $3.19 | +1.92% | -3.45% | -4.11% |
| Jul 31, 2025after close | $3.07 | $3.13 | +1.95% | -3.80% | -4.17% |
| May 1, 2025after close | $2.73 | $2.84 | +4.03% | +1.13% | +2.26% |
| Jan 28, 2025after close | $3.87 | $4.01 | +3.62% | -1.03% | -0.70% |
| Oct 29, 2024after close | $2.77 | $2.87 | +3.61% | +1.23% | +3.02% |
As of October 16, 2026, SYK has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 30, 2026, came in 5.73% above the estimate and the stock moved -6.42% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 57.6, in neutral territory.RSI above 50 ›
An RSI of 57.6 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of SYK
The score, the reasoning behind it, and what could move the price next.
The stock's current price of $293.23 is positioned between its 20-day EMA and 50-day SMA. Key support levels are near the 50-day SMA, while resistance lies at the 200-day SMA. Volume on the latest trading day was 3.12 million, significantly above the average of 2.38 million, indicating increased investor interest. The chart structure suggests a period of consolidation or potential reversal as it tests the 50-day SMA.
Strong Analyst Consensus and Price Targets ›
A 'Buy' consensus from 29 analysts with a median price target of $360 suggests significant upside potential of 22.8% from the current price, indicating Wall Street's confidence in future performance.
Source: Wall Street AnalystsAbove Sector Average Revenue Growth ›
Stryker's revenue growth of 9.4% exceeds the Healthcare sector median of 8.1%, signaling strong market demand and effective business expansion strategies.
Source: Company Fundamentals
Trading Below Key Moving Averages ›
The stock is currently trading below its 50-day and 200-day moving averages ($300.80 and $326.94), suggesting a bearish technical trend and potential for further downside.
Source: Technical Analysis
- Significant insider selling pressure, indicated by a 'Heavy Sell Signal' and $738.2 million in dispositions, warrants close monitoring of future insider activity and company performance.
- The stock's current position below its 50-day and 200-day moving averages ($300.80 and $326.94) suggests caution, and investors may consider waiting for a confirmed break above these levels before initiating or adding to positions.
- With a dividend yield of 1.20%, SYK offers a modest income component, but the primary investment thesis should focus on capital appreciation driven by its growth prospects and analyst targets.
Key catalysts for upside include continued innovation in medical devices and potential market share gains. Downside risks are primarily centered around the heavy insider selling and the stock's current technical weakness. A sustained break above the 50-day and 200-day moving averages would be a key signal for a bullish reversal.
Technical indicators
Momentum and trend for SYK, from its daily closes.
As of October 16, 2026, with SYK at $293.23, its 14-day RSI is 57.6 (neutral territory), its 50-day simple moving average is $300.80 and its 200-day is $326.94.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What SYK moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, SYK's 1-year correlation of daily returns is +0.35 with S&P 500 (SPY), +0.19 with Nasdaq 100 (QQQ), -0.05 with Bitcoin (BTC) and +0.00 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
23 of 29 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $360.00 is 22.8% above the price.More buy ratings than three months ago ›
23 of 29 rate it a buy now, against 23 of 28 three months ago.
SYK Wall Street View
12-month price targets
The price, $293.23, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Truist Securities | Maintains | Hold |
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Sep 30, 2026 | Stifel | Maintains | Buy |
| Sep 22, 2026 | TD Cowen | Maintains | Hold |
| Sep 18, 2026 | Canaccord Genuity | Maintains | Buy |
| Sep 10, 2026 | Citigroup | Maintains | Buy |
As of October 16, 2026, 29 Wall Street analysts cover SYK: 23 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $298.00 to $465.00, with a median of $360.00, 22.8% above the price of $293.23.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
SYK trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from SYK's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much SYK tends to move, against the market and on its own.
The long record
SYK's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 2.27% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 33.4%, from February 2020 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
76% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $28,825, against $42,525 in the S&P 500 (SPY).
SYK Drawdowns & Recovery
As of October 16, 2026, SYK's worst peak-to-trough fall over the last 10 years with dividends reinvested was -33.4% (February 2020 to March 2020); it regained that peak by November 2020, 8 months after the low, and 76% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into SYK in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: SYK trailed the S&P 500 over this period: $28,825 against $42,525.
A $10,000 investment in SYK in October 2016 would be worth about $28,825 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to SYK, and which have not.
Strongest month, January: an average of +4.56%, up in 9 of 10 years.
Weakest month, March: an average of -2.26%, up in 4 of 10 years.
This month, October: has averaged +1.41%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, SYK's strongest calendar month has been January (average +4.56%, up in 9 of 10 years) and its weakest March (average -2.26%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in SYK, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in SYK today could grow to about $21,060 by 2036 in the base case, with a 90th-percentile outcome near $63,162 and a 10th-percentile outcome around $7,022. The simulation models price only; at today's 1.20% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
SYK Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $395 for SYK by 2030 in the base case, from $293 today (1.3x over 4 years). The 10th-percentile path ends near $197. These are outcomes of a Monte Carlo simulation run on SYK's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $223 | $316 | $447 | |
| 2028 | $208 | $340 | $556 | |
| 2029 | $201 | $367 | $669 | |
| 2030 | $197 | $395 | $791 | |
| 2031 | $196 | $426 | $925 |
Method: a lognormal simulation of SYK's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
SYK insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought SYK shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, SYK insiders reported 16 open-market sales worth $738.2M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Dylan Bram Crotty
Officer
|
Sell | 441 | $144.9K |
| Aug 19, 2026 | Ronda E Stryker
Director
|
Sell | 350.0K | $117.8M |
| Aug 18, 2026 | Debra King
Officer
|
Sell | 826 | $277.8K |
| Jun 1, 2026 | Spencer S Stiles
President
|
Grant | 1.6K | - |
| May 28, 2026 | Robert S Fletcher
Officer
|
Sell | 4.5K | $1.4M |
| May 26, 2026 | Ronda E Stryker
Director
|
Sell | 310.0K | $96.8M |
| May 11, 2026 | Mary Kathryn Fink
Officer
|
Sell | 8.7K | $2.5M |
| May 8, 2026 | Mary Kathryn Fink
Officer
|
Option | 21.6K | $3.6M |
| May 6, 2026 | Mary K Brainerd
Director
|
Grant | 762 | - |
| May 6, 2026 | Giovanni Caforio
Director
|
Grant | 762 | - |
| May 6, 2026 | Debra King
Chief Technology Officer
|
Grant | 1.0K | - |
| May 6, 2026 | Emmanuel Perez Maceda
Director
|
Grant | 762 | - |
| May 6, 2026 | Sherilyn S Mccoy
Director
|
Grant | 762 | - |
| May 6, 2026 | Kimberly Ann Montagnino
Officer
|
Grant | 677 | - |
| May 6, 2026 | Rachel Ruggeri
Director
|
Grant | 762 | - |
| May 6, 2026 | Andrew K. Silvernail
Director
|
Grant | 762 | - |
| May 6, 2026 | Tatum Lisa M Skeete
Director
|
Grant | 762 | - |
| May 6, 2026 | Ronda E Stryker
Director
|
Grant | 762 | - |
| May 6, 2026 | Rajeev Suri
Director
|
Grant | 762 | - |
| Mar 20, 2026 | Mary Kathryn Fink
Officer
|
Grant | 150 | - |
| Mar 20, 2026 | Robert S Fletcher
Officer
|
Grant | 225 | - |
| Mar 20, 2026 | Kevin A Lobo
Chief Executive Officer
|
Grant | 1.5K | - |
| Mar 20, 2026 | Viju S Menon
Officer
|
Grant | 269 | - |
| Mar 20, 2026 | James Andrew Pierce
Officer
|
Grant | 430 | - |
| Mar 20, 2026 | Spencer S Stiles
President
|
Grant | 430 | - |
| Mar 9, 2026 | Mary Kathryn Fink
Officer
|
Grant | 5.2K | - |
| Mar 9, 2026 | Robert S Fletcher
Officer
|
Grant | 7.8K | - |
| Mar 9, 2026 | Kevin A Lobo
Chief Executive Officer
|
Grant | 50.3K | - |
| Mar 9, 2026 | Viju S Menon
Officer
|
Grant | 9.3K | - |
| Mar 9, 2026 | James Andrew Pierce
Officer
|
Grant | 14.9K | - |
| Mar 9, 2026 | Spencer S Stiles
President
|
Grant | 14.9K | - |
| Feb 23, 2026 | Ronda E Stryker
Director
|
Grant | 55.6K | - |
| Feb 17, 2026 | Ronda E Stryker
Director
|
Grant | 600.2K | - |
| Feb 6, 2026 | Kevin A Lobo
Chief Executive Officer
|
Option | 207.0K | $20.0M |
| Feb 5, 2026 | Ronda E Stryker
Director
|
Sell | 500.0K | $181.7M |
| Feb 4, 2026 | William E Berry Jr
Officer
|
Grant | 797 | - |
| Feb 4, 2026 | James Andrew Pierce
Officer
|
Grant | 2.8K | - |
| Feb 3, 2026 | Spencer S Stiles
President
|
Option | 13.8K | $1.3M |
| Feb 2, 2026 | James Andrew Pierce
Officer
|
Sell | 475 | $175.2K |
| Feb 2, 2026 | James Andrew Pierce
Officer
|
Option | 13.8K | $1.3M |
| Jan 15, 2026 | Andrew K. Silvernail
Director
|
Option | 4.6K | $441.6K |
| Jan 14, 2026 | Ronda E Stryker
Director
|
Option | 4.6K | $441.6K |
| Nov 21, 2025 | James Andrew Pierce
Officer
|
Grant | 211 | - |
| Nov 20, 2025 | Preston Wendell Wells
Chief Financial Officer
|
Sell | 165 | $60.4K |
| Nov 14, 2025 | William E Berry Jr
Officer
|
Sell | 2.0K | $713.8K |
| Nov 14, 2025 | William E Berry Jr
Officer
|
Option | 4.9K | $759.1K |
| Nov 6, 2025 | Ronda E Stryker
Director
|
Sell | 520.0K | $184.6M |
| Aug 25, 2025 | Viju S Menon
Officer
|
Sell | 500 | $195.3K |
| Aug 20, 2025 | Robert S Fletcher
Officer
|
Sell | 1.8K | $701.6K |
| Aug 6, 2025 | Ronda E Stryker
Director
|
Sell | 200.0K | $75.3M |
| Aug 5, 2025 | Mary Kathryn Fink
Officer
|
Grant | 917 | - |
| Aug 5, 2025 | Debra King
Chief Technology Officer
|
Grant | 6.6K | - |
| May 12, 2025 | William E Berry Jr
Officer
|
Sell | 1.2K | $482.2K |
| May 8, 2025 | Mary K Brainerd
Director
|
Grant | 560 | - |
| May 8, 2025 | Giovanni Caforio
Director
|
Grant | 560 | - |
| May 8, 2025 | Emmanuel Perez Maceda
Director
|
Grant | 560 | - |
| May 8, 2025 | Rachel Ruggeri
Director
|
Grant | 560 | - |
| May 8, 2025 | Andrew K. Silvernail
Director
|
Grant | 560 | - |
| May 8, 2025 | Tatum Lisa M Skeete
Director
|
Grant | 560 | - |
| May 8, 2025 | Ronda E Stryker
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 560 | - |
| May 8, 2025 | Rajeev Suri
Director
|
Grant | 560 | - |
| May 6, 2025 | Ronda E Stryker
Director and Beneficial Owner of more than 10% of a Class of Security
|
Sell | 200.0K | $75.4M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.